Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Chlorhexidine gluconate · 1 trial · 1 indication
Clinician Overall Satisfaction with Catheter Securement Five Point Scale: 1 = Very Good, 5= Very Poor
| Arm | Type | Description |
|---|---|---|
| Transparent Adhesive Dressing | PLACEBO_COMPARATOR | Standard of Care Non-Antimicrobial Transparent Adhesive Dressing |
| CHG antimicrobial transparent dressing | EXPERIMENTAL | Chlorhexidine gluconate antimicrobial transparent adhesive dressing |
| Name | Type | Description |
|---|---|---|
| Chlorhexidine gluconate | DRUG | 2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear |
| Transparent Adhesive Dressing | DRUG | Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear |
Inclusion Criteria: * Males or Females over 18 years of age * Patients with an existing, or newly inserted, central venous catheter * Patients who require the catheter for at least 3 days Exclusion Criteria: * Sensitivity to chlorhexidine
Chlorhexidine gluconate is an investigational small molecule being studied for use in catheterization. It is being evaluated as an antimicrobial dressing to reduce infection risk associated with catheter use. The drug is currently in Phase 2 clinical development and has not been approved for this indication.
Chlorhexidine gluconate is an antimicrobial agent that works by disrupting microbial cell membranes, leading to cell death. It is being studied for its ability to reduce bacterial colonization at catheter insertion sites, thereby potentially preventing catheter-related infections. The drug is in Phase 2 development for catheterization.
Chlorhexidine gluconate is being developed by Solventum Corporation, which trades under the ticker SOLV. The company is conducting clinical research to evaluate the drug's safety and efficacy for use in catheterization. The drug is currently in Phase 2 clinical trials.
Chlorhexidine gluconate is in Phase 2 clinical development for catheterization. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing for this indication.
Chlorhexidine gluconate has one completed Phase 2 clinical trial, NCT00516906, titled 'Clinical Performance of a Chlorhexidine Antimicrobial Dressing.' This randomized, placebo-controlled study enrolled 68 participants aged 18 years and older to evaluate the dressing's performance in catheterization. The trial is completed.
Chlorhexidine gluconate is a salt form of chlorhexidine, a well-known antiseptic. In this context, it is being studied as an antimicrobial dressing for catheterization. The drug is in Phase 2 development by Solventum Corporation and is not yet approved for this use.